logo
  Join        Login             Stock Quote

Keryx Biopharmaceuticals (KERX) Starts Chronic Kidney Disease Treatment Study

 November 01, 2012 10:49 AM
 


(By Balaseshan) Keryx Biopharmaceuticals (NASDAQ: KERX) said it has initiated a phase 2 study of Zerenex (ferric citrate) for the treatment of patients with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).

Zerenex is the company's ferric iron-based phosphate binder drug candidate for managing serum phosphorus and iron deficiency in anemic patients with NDD-CKD.

In the United States alone, over one and a half million people suffering from Stages 3 to 5 NDD-CKD have iron deficiency anemia, however, there are currently no oral iron supplements with an FDA label in NDD-CKD. Also, there are currently no FDA approved phosphate binders in NDD-CKD.

[Related -Stocks Off Over 1 Pct After Bernanke Comments; VIVUS, Inc. (VVUS) Gains]

The phase 2 study initiated today is a multicenter, randomized, safety and efficacy clinical trial designed to compare the ability of Zerenex to manage serum phosphorus and iron deficiency versus placebo in anemic patients with stages 3 to 5 NDD-CKD. Eligible patients will be randomized 1:1 to receive either Zerenex or placebo for a 12-week treatment period.

The primary endpoints of the study are to demonstrate changes in ferritin, TSAT and serum phosphorus levels over the 12-week treatment period. Secondary endpoints include changes in hemoglobin and FGF-23.

The study plans to randomize about 150 patients from about 15 sites in the U.S. Patient enrollment is expected to take up to 6 months, with study completion expected in mid-2013.

[Related -A Down Day For The Indices]

Zerenex is currently also in a long-term phase 3 study, under special protocol assessment, as treatment for end-stage renal disease patients with hyperphosphatemia on dialysis. Top-line data from this Phase 3 study is expected to be announced by approximately year-end 2012, with the NDA filing expected in the first quarter of 2013 for this indication.

Keryx Biopharmaceuticals retains a worldwide exclusive license (except for the Asian Pacific Region) to Zerenex (ferric citrate) from Panion & BF Biotech Inc. The company has sublicensed the development of ferric citrate in Japan to Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

It is estimated that about 10 percent to 15 percent of the U.S. adult population is affected by chronic kidney disease (CKD), a condition generally characterized by greater than 50 percent reduction of normal kidney function. In addition, elevated levels of serum phosphorus become more prevalent in stages 3 to 5 non-dialysis dependent CKD (NDD-CKD) patients.

Several studies have shown that higher serum phosphorus concentrations may be associated with increased mortality and morbidity in CKD, however, no phosphate binders are currently FDA approved for NDD-CKD.

KERX is trading down 0.80 percent at $2.47 on Thursday. The stock has been trading between $1.28 and $5.19 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Mixed, Productive Day
More Articles on: Finance , Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.